Publications & Presentations

We would like to thank our patients for their participation in research studies. Your contribution has made a lasting impact on the field and will advance the care of future patients!

Selected Publications and Presentations

• Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network
• A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot Study
• Use of the BASDAI in Psoriatic Arthritis Patients With and Without Axial Disease
• The impact of dietary interventions in psoriatic arthritis
• H. Ralph Schumacher
• Corticosteroid Injections for Symptomatic Treatment of Osteoarthritis of the Knee: A Pilot Blinded Randomized Trial
• Associations between Adiponectin and the Development of Diabetes in Rheumatoid Arthritis
• Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis
• Changes in Patterns of Use of Advanced Therapies Following Emerging Data About Adverse Events in Patients With Rheumatoid Arthritis From the Veterans Affairs Health System
• Identifying Factors Associated With Treatment Response in Rheumatoid Arthritis Clinical Trials
• Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study

PubMed Feed

• Performance of Risk Score Calculators in the Identification of Coronary Artery Calcification in Patients with Systemic Lupus Erythematosus.
  The Journal of rheumatology. 2025 Nov 15; Authors: Patel H, Stoots S, Von Feldt J, Baker JF

• Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs).
  Arthritis care & research. 2025 Nov 10; Authors: O'Sullivan ML, Cannon GW, Sauer BC, Rojas J, Kunkel GA, Walsh JA, Patel S, Roul P, Baker JF, England BR, Mikuls TR, Braaten TJ

• Frailty carries an increased risk of death in rheumatoid arthritis.
  Seminars in arthritis and rheumatism. 2025 Nov 7;75:152872; Authors: Bhide SA, Roul P, England BR, Brubeck HF, Cannon GW, Singh N, Loecker C, Kunkel G, Mikuls TR, Shoback DM, Michaud K, Katz PP, Garcia JM, Orkaby AR, Baker JF, Wysham KD

• Agreement of Administrative Pharmacy Dispensing With Self-Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis.
  Arthritis care & research. 2025 Nov;77(11):1350-1358 Epub 2025 Aug 8; Authors: Wallace BI, England BR, Baker JF, George MD, Sauer BC, Rojas J, Roul P, Wysham KD, Brubeck H, Smith I, Caplan L, Monach PA, Kerr GS, Kunkel G, Braaten T, Mikuls TR, Cannon GW

• Antimicrobial Use and Serious Infections Among Patients With Psoriatic Arthritis After Initiating Tumor Necrosis Factor Inhibitors: A Nationwide Matched Cohort Study.
  The Journal of rheumatology. 2025 Nov 1;52(11):1098-1106; Authors: Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ, ICEBIO

• Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry.
  ACR open rheumatology. 2025 Nov;7(11):e70109; Authors: Baker JF, Mizelle KV, Saikali W, Moore PC, Kang HJ, Gruben D, Shelbaya A, Stockert L, O'Brien J

• Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4(+) T Cells.
  European journal of immunology. 2025 Nov;55(11):e70093; Authors: Williams L, Saber AO, Awad S, Su X, Ansari A, Xu R, Jung H, Shahane A, Baker JF, Su LF

• Exploring Factors Associated with Cognitive Impairment in Rheumatoid Arthritis.
  Arthritis care & research. 2025 Oct 28; Authors: Dawood R, Brubeck HF, Riggles KE, Sattui SE, Myasoedova E, Makris UE, Shoback DM, Garcia JM, Orkaby AR, Baker JF, Katz PP, Wysham KD

• Burden of Disease and Drug Response for Patients with Rheumatoid Arthritis by Shared Epitope and Anti-Citrullinated Protein Antibody Status.
  The Journal of rheumatology. 2025 Oct 15; Authors: Wipfler K, Baker JF, Sayles H, Park SH, Wittstock K, Mikuls TR, Michaud K

• Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
  Nature medicine. 2025 Oct 6; Authors: McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF